NAYA Biosciences (Nasdaq:NAYA) - Stock Price, News & Analysis

NAYA Stock Overview

Focuses on developing clinical and commercial-stage assets for fertility, oncology, and autoimmune diseases. More details

NAYA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Does not have a meaningful market cap ($4M)

Volatile share price over the past 3 months compared to the US market

NAYA Biosciences, Inc. Competitors

Talis Biomedical

OTCPK:TLIS

US$3.2m

ReShape Lifesciences

NasdaqCM:RSLS

US$4.0m

ENDRA Life Sciences

NasdaqCM:NDRA

US$3.1m

Predictive Oncology

NasdaqCM:POAI

US$5.3m

Price History & Performance

Summary of all time highs, changes and price drops for NAYA Biosciences
Historical stock prices
Current Share Price	US$0.94
52 Week High	US$1.24
52 Week Low	US$0.72
Beta	0
11 Month Change	9.37%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-8.33%

Recent updates

Shareholder Returns

	NAYA	US Medical Equipment	US Market
7D	3.9%	1.7%	1.6%
1Y	n/a	22.5%	32.3%

Return vs Industry: Insufficient data to determine how NAYA performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how NAYA performed against the US Market.

Price Volatility

Is NAYA's price volatile compared to industry and market?
NAYA volatility
NAYA Average Weekly Movement	14.4%
Medical Equipment Industry Average Movement	7.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: NAYA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine NAYA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Steve Shum	nayabiosciences.com

NAYA Biosciences, Inc. focuses on developing clinical and commercial-stage assets for fertility, oncology, and autoimmune diseases. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma; and NY-338, a CD38-targeted FLEX-NK bispecific antibody for multiple myeloma and autoimmune diseases. The company also offers INVOcell, an IVC device that is an alternative to IVF that uses the female body for fertilization and incubation.

NAYA Biosciences, Inc. Fundamentals Summary

How do NAYA Biosciences's earnings and revenue compare to its market cap?
NAYA fundamental statistics
Market cap	US$3.63m
Earnings (TTM)	US$0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is NAYA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NAYA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$0
Earnings	US$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did NAYA perform over the long term?

See historical performance and comparison

NAYA Biosciences NasdaqCM:NAYA Stock Report